Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT – Get Free Report) have been given a consensus rating of “Moderate Buy” by the ...

PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. It manufactures and sells the AquaBeam Robotic ...

TD Cowen lowered the firm’s price target on Procept BioRobotics (PRCT) to $85 from $99 and keeps a Buy rating on the shares. The firm notes sales topped estimates as the Hydros rollout continues ...

Good afternoon and welcome to Procept Biorobotics fourth quarter and year-end 2024 earnings conference call. (Operator Instructions) As a reminder, this call is being recorded for replay purposes.

Analysts' ratings for PROCEPT BioRobotics PRCT over the last quarter vary from bullish to bearish, as provided by 4 analysts. The table below provides a concise overview of recent ratings by ...

PROCEPT BioRobotics SAN JOSE, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing ...

PROCEPT BioRobotics shows strong revenue growth and expanding market presence but struggles with profitability and rising operational costs. The company’s HYDROS robotic system and consumables ...

PROCEPT BioRobotics, which belongs to the Zacks Medical - Instruments industry, posted revenues of $68.24 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 2.40%.

Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT – Free Report) by 4.9% in the fourth quarter, according to the company in its most recent ...

A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the Company’s website at https://ir.procept-biorobotics.com/. The webcast will be ...